PMID- 26471890
OWN - NLM
STAT- MEDLINE
DCOM- 20160524
LR  - 20220316
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 11
IP  - 4
DP  - 2015 Dec
TI  - Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for 
      colon cancer in clinical practice: Outcomes of the ACCElox registry.
PG  - 334-42
LID - 10.1111/ajco.12409 [doi]
AB  - AIM: The ACCElox registry was set up to assess therapeutic management of 
      early-stage colon cancer with oxaliplatin/5-fluorouracil (5-FU)-based regimen and 
      the duration of adjuvant chemotherapy in current clinical practice. METHODS: This 
      prospective observational study was conducted between 2006 and 2008 in 19 
      countries on 1548 newly diagnosed patients with stage II/III colon cancer, who 
      had complete resection of the primary tumor and treated with at least one dose of 
      oxaliplatin. The patient/disease characteristics, dose intensity, toxicity 
      management, treatment delay and duration of disease-free survival (DFS)/relapse 
      were assessed. RESULTS: About 73 and 27% of the patients were diagnosed with 
      stage III (Dukes C) and stage II (Dukes B2) colon cancer, respectively. Overall, 
      74.4% patients completed the prescribed chemotherapy (FOLFOX 88%) and 97.6% 
      patients received at least two cycles of oxaliplatin chemotherapy. The median 
      actual dose intensity of oxaliplatin per cycle was 85 mg/m(2) . Relapse within 3 
      years occurred in 18.4% of patients with similar rate in all three groups (FOLFOX 
      - 18.1%, FLOX - 19%, XELOX - 18.6%). At 3 years follow-up only 72 deaths were 
      reported. The most common adverse events (AEs) at any cycle were neutropenia 
      (63.9%), thrombocytopenia (23.3%), diarrhea (9.7%), sensory neuropathy (4.5%) and 
      infection (2.6%). Disorders of central and peripheral nervous systems were 
      frequently reported AEs at 6 months (54.3%, grade >/=1) and 12 months (36.4%, 
      grade >/=1) of follow-up. CONCLUSION: Majority of the patients completed the 
      prescribed oxaliplatin/5-FU regimen. There was no significant difference in the 
      DFS among these regimens. Our results confirm the favorable benefit/risk profile 
      of oxaliplatin/5-FU-based regimens in this setting in clinical practice.
CI  - (c) 2015 Wiley Publishing Asia Pty Ltd.
FAU - Park, Young Suk
AU  - Park YS
AD  - Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South 
      Korea.
FAU - Ji, Jiafu
AU  - Ji J
AD  - Beijing Cancer Hospital, Beijing, China.
FAU - Zalcberg, John Raymond
AU  - Zalcberg JR
AD  - Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - El-Serafi, Mostafa
AU  - El-Serafi M
AD  - National Cancer Institute, University of Cairo, Giza, Egypt.
FAU - Buzaid, Antonio
AU  - Buzaid A
AD  - Hospital Sirio Libanes, Sao Paulo, Brazil.
FAU - Ghosn, Marwan
AU  - Ghosn M
AD  - Hotel-Dieu de France Hospital, Beirut, Lebanon.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20151015
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Organoplatinum Compounds)
RN  - 04ZR38536J (Oxaliplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Colonic Neoplasms/*drug therapy/mortality/pathology
MH  - Female
MH  - Fluorouracil/administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy/mortality/pathology
MH  - Neoplasm Staging
MH  - Organoplatinum Compounds/administration & dosage
MH  - Oxaliplatin
MH  - *Practice Patterns, Physicians'
MH  - Prognosis
MH  - Prospective Studies
MH  - *Standard of Care
MH  - Survival Rate
MH  - Young Adult
OTO - NOTNLM
OT  - adjuvant chemotherapy
OT  - neutropenia
OT  - oxaliplatin
OT  - sensory neuropathy
OT  - thrombocytopenia
EDAT- 2015/10/17 06:00
MHDA- 2016/05/25 06:00
CRDT- 2015/10/17 06:00
PHST- 2015/07/05 00:00 [accepted]
PHST- 2015/10/17 06:00 [entrez]
PHST- 2015/10/17 06:00 [pubmed]
PHST- 2016/05/25 06:00 [medline]
AID - 10.1111/ajco.12409 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2015 Dec;11(4):334-42. doi: 10.1111/ajco.12409. Epub 2015 
      Oct 15.